Patents by Inventor Bruno DOMBRECHT

Bruno DOMBRECHT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biologic compounds directed against death receptor 5
    Patent number: 9120855
    Abstract: The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: September 1, 2015
    Assignee: NOVARTIS AG
    Inventors: Karen Cromie, Bruno Dombrecht, Seth Ettenberg, Joost Kolkman, Jing Li, Kris Meerschaert, David Raymond Stover, Jingxin Zhang
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20150050266
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: December 23, 2013
    Publication date: February 19, 2015
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • PSEUDOMONAS AERUGINOSA PCRV BINDING SINGLE VARIABLE DOMAIN ANTIBODIES
    Publication number: 20150044215
    Abstract: Polypeptides are provided that are capable of significantly inhibiting andor neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Application
    Filed: March 4, 2013
    Publication date: February 12, 2015
    Applicant: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • SERUM ALBUMIN BINDING PROTEINS
    Publication number: 20140228546
    Abstract: The present invention relates to amino acid sequences that are capable of binding to serum albumin; to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.
    Type: Application
    Filed: June 14, 2012
    Publication date: August 14, 2014
    Applicant: Ablynx N.V.
    Inventors: Bruno Dombrecht, Peter Schotte, Cedric Josef Neotere Ververken
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20140205597
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: December 23, 2013
    Publication date: July 24, 2014
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • CHEMOKINE RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20140050736
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Application
    Filed: October 29, 2013
    Publication date: February 20, 2014
    Applicant: NOVARTIS AG
    Inventors: Michelle BRADLEY, Zarin BROWN, Steven John CHARLTON, Karen CROMIE, Bruno DOMBRECHT, Soren STEFFENSEN, Gino Anselmus VAN HEEKE
  • Chemokine receptor binding polypeptides
    Publication number: 20130330346
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Application
    Filed: May 3, 2013
    Publication date: December 12, 2013
    Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • Chemokine receptor binding polypeptides
    Patent number: 8591896
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: November 26, 2013
    Assignee: Novartis AG
    Inventors: Michelle Bradley, Zarin Brown, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Van Heeke
  • CHEMOKINE RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20120183549
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Application
    Filed: November 7, 2011
    Publication date: July 19, 2012
    Applicant: NOVARTIS AG
    Inventors: Michelle BRADLEY, Zarin BROWN, Steven John CHARLTON, Karen CROMIE, Bruno DOMBRECHT, Soren STEFFENSEN, Gino VAN HEEKE
  • BIOLOGIC COMPOUNDS
    Publication number: 20110318366
    Abstract: The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.
    Type: Application
    Filed: February 9, 2011
    Publication date: December 29, 2011
    Applicants: ABLYNX NV, NOVARTIS AG
    Inventors: Karen CROMIE, Bruno DOMBRECHT, Seth ETTENBERG, Joost KOLKMAN, Jing LI, Kris MEERSCHAERT, David Raymond STOVER, Jingxin ZHANG